Stock Analiz

Jyong Biotech Ltd. MENS

Biotechnology: Pharmaceutical Preparations · IPO 2025 · data as of November 13, 2026

$1.76Market cap $134M
Open the interactive analysis →

Jyong Biotech Ltd. (MENS) is a healthcare company listed in the US with a market value of about $134M.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).

About Jyong Biotech

Jyong Biotech is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2025. It was profitable in 0 of the last 3 years in our data.

Score: 0.2 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)—
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 3 years

Fiscal year202520242023
Revenue———
Net income-$5M-$3M-$4M
Free cash flow———
EPS (diluted)$-0.06$-0.04$-0.06
Net margin———
ROIC———

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Jyong Biotech pay a dividend?

Not currently.

Is Jyong Biotech a good stock to buy?

We do not give buy or sell advice. Jyong Biotech scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.